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Introduction
Alzheimer’s disease (AD) aﬀ  ects millions worldwide and 
is associated with tremendous human and ﬁ  nancial costs. 
Because the prevalence of AD is increasing and no 
medications alter disease progression, there is great need 
for new therapies. Developing these therapies relies upon 
the clinical trial, but AD trials face challenges. Th  is 
review focuses on the challenges to eﬀ  ective recruitment 
and retention of participants. Th   e failure to address these 
challenges has a number of costs. It can halt a trial, 
render a scientiﬁ   c question unanswered, and waste 
precious resources—most critically the time, eﬀ  ort, and 
health of participants.
After a review of the literature and experiences in AD 
clinical trial conduct, this paper summarizes the 
challenges related to AD trial recruitment and retention 
for phase II and phase III randomized, placebo-controlled 
trials of treatments that target the underlying biology or 
cognitive symptoms associated with AD. We discuss how 
trial design and conduct can aﬀ   ect recruitment. We 
examine why recruited participants may not adequately 
represent the greater disease-suﬀ   ering population. We 
overview the barriers to recruitment related to the study 
participants: both AD patients and their study partners. 
We discuss the challenges to retention of participants in 
AD trials. To address these issues, we propose changes to 
study recruitment practices and attempt to guide 
investigators to consider potential pitfalls in the way they 
conduct recruitment and retention.
Trial design and conduct can aff  ect recruitment
Success in meeting enrollment goals is not simply about 
advertising and outreach. Studies that are too long, 
require too many visits, or target enrollment of a 
population too diﬃ   cult to recruit are in danger of slow or 
inadequate enrollment. In Table 1, we provide a literature 
summary of the rates of recruitment to a sample of 
multicenter AD trials. For these trials, we have calculated 
a summary recruitment rate statistic (RR) that is an 
approximation of the number of subjects recruited per 
study site per month for a given trial. Every trial faces 
unique challenges to recruitment, and every trial has its 
own recruitment goals. As such, comparisons among 
trials must be made carefully. Moreover, the data within 
Table 1 speak only to the rapidity with which a trial 
reached full enrollment. Timely fulﬁ   llment of the 
proposed study enrollment is only one part of a truly 
‘successful’ recruitment. Perhaps more important is the 
recruitment of a population of participants who are likely 
to complete the trial, are indeed aﬄ   icted with AD, and 
are representative of others with AD who will not be 
enrolled. Within a given trial, choices related to study 
design have a major impact on whether a trial achieves 
successful enrollment.
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trials. Unfortunately, clinical trials often suff  er from 
slow or insuffi   cient enrollment. Successful clinical 
trial recruitment describes a balance between 
expeditiously achieving full enrollment and ensuring 
an appropriate study sample. Investigators face a 
number of challenges to the successful negotiation of 
this balance. The failure to address these challenges 
means that drug development may take more time 
and money and that trial results may not adequately 
represent drug effi   cacy or may not be applicable 
beyond the study. We review the challenges to 
recruitment and retention in Alzheimer’s disease 
clinical trials and present a framework to address them.
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Decisions related to the total length of a study and the 
frequency of study visits are guided by study goals and 
often by concerns over safety. It is logical to expect that 
the longer the study and the greater the number of study 
visits, the greater the burden on participants and the 
more diﬃ   cult recruitment will be. Trials of agents with 
high risk proﬁ  les or for which the risk proﬁ  le is largely 
unknown often require more visits to ensure patient 
safety. For example, early-phase studies (phase I or IIa) 
are often shorter (on the order of weeks to months) and 
require more frequent study visits than later-phase 
studies. Phase II AD trials of gamma secretase inhibitors 
have commonly used every-other-week study visits [1], 
making participation more daunting, espe  cially for 
individuals who travel great distances to parti  ci  pate. In 
contrast, late-phase studies (phase IIb or III) that aim to 
evaluate eﬃ   cacy are commonly at least 18 months long. 
Th  ese trials generally use study visits every 3  months. 
Less commonly, the intervention itself necessi  tates a 
more frequent rate of study visits. Ongoing trials of some 
immunotherapies for AD use medication infu  sions once 
or twice per month.
Selection of the targeted Alzheimer’s disease population
Th  e target population is deﬁ   ned by the inclusion and 
exclusion criteria that participants must meet to enroll. 
Inclusion criteria should be designed to enroll only 
patients who truly suﬀ  er from AD and to maximize the 
likelihood of demonstrating a diﬀ  erence between drug 
and placebo when one exists [2]. Inclusion criteria 
generally identify a patient population of a speciﬁ  c 
disease severity. Th   is is most often deﬁ  ned by a range of 
scores on the Mini-Mental State Examination (MMSE) 
[3]. Challenges in enrollment are not limited to trials of 
speciﬁ  c disease severities. As can be seen in the sample of 
published AD trials described in Table 1, examples of 
studies with fast rates of enrollment (for example, RR >1) 
Table 1. Recruitment rates from a sample of Phase II and Phase III Alzheimer’s disease clinical trials
   Study    Enrollment,        Screen
  Treatment under study  enrollment  Sites  months  RRa Screened  ratiob
Mild cognitive impairment  Rofecoxib [54]  1,457  46  24  1.32  2,849  1.95
  Rivastigmine  [55]  1,018  65  12  1.30 1,526 1.50
  Two studies of galantamine [56]  2,057  177  12  0.97  2,759  1.35
  Donepezil  [57]  270  22  16  0.77 588 2.18
  Vitamin E and donepezil [38]  790  69  23  0.49  2,264  2.87
  TRIMCI study of trifusal [7]  257c 29  24 0.36 NA NA
  Donepezil  [58]  821  91  28  0.32 2,037 2.48
Mild-to-moderate AD  Dimebon [59]  183  11  6  2.77  230  1.26
  Idebenone  [60]  536  39  12  1.14 729 1.36
  DHA (Joseph Quinn, personal communication)  402  52  8  0.96  555  1.39
 AN1792  [61]  372  28  16  0.83  NA  NA
  Rofecoxib  [37]  351  40  11  0.80 474 1.35
  Tarenfl   urbil  [9]  1,684 133  21  0.60 2,408 1.43
  Gamma secretase inhibitor [62]  51  6  51  0.57  71  1.39
  Rivastigmine patch [63,64]  1,195  100  22  0.54  1,464  1.22
  Bapineuzumab  [10]  234  30  16  0.49 317 1.35
  Rosiglitazone  [65]  518  67  17  0.45 687 1.33
  High-dose B vitamin [66]  409  40  27  0.26  601  1.47
  Estrogen replacement [6]  120  39  32  0.10  153  1.27
Moderate-to-severe/Severe AD  Memantine [13]   404  37  6  1.82  589  1.46
  Memantine [12]   252  32  9  0.875  345  1.37
  Memantine [67]   350  35  17  0.59  547  1.56
  Donepezil [5]   249  50  18  0.28  334  1.34
  Donepezil [68]   343  91  44  0.09  543  1.58
aRecruitment rate statistic, number of participants per site per month. Reported numbers are gross estimates from data reported in publications rather than 
exact calculations of recruitment rates averaged across study sites. bNumber of patients screened for every enrolled subject. cFailed to meet enrollment goals. AD, 
Alzheimer’s disease; DHA, docosahexaenoic acid; NA, not available.
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can occur in trials in all stages of disease severity. Trials 
that fail to complete enrollment are also likely to go 
unpublished, given the probability that they will fail to 
meet the primary outcome [4]. To be clear, recruitment 
of participants with more severe disease faces unique 
challenges in comparison with studies of milder disease. 
Careful design and unique recruitment strategies, how-
ever, can be undertaken to overcome such challenges [5].
Besides disease severity, other speciﬁ  cations related to 
the population to be recruited can impact the rate of 
enrollment. For example, the Alzheimer’s Disease Co-
operative Study (ADCS) trial of estrogen replacement 
enrolled only women who had mild-to-moderate AD and 
who had undergone hysterectomy. Despite a somewhat 
wider range of MMSE inclusion criteria (12 to 28) than is 
typical, this trial enrolled only an average 10 subjects per 
month across 39 sites, and it took more than 3 years to 
complete enrollment [6].
Medication-related decisions
Criteria that exclude a large number of concomitant 
medications, though often necessary to ensure partici-
pant safety, can hinder recruitment. Many AD patients 
take supplements such as ginkgo biloba, and some trials 
exclude these patients. Alternatively, in trials examining 
available medications or supplements for therapeutic 
beneﬁ  t in AD, the greater availability of these agents can 
pose a challenge to enrollment. Th   e TRIMCI study of the 
anti-inﬂ   ammatory agent trifusal in amnestic mild 
cognitive impairment (MCI) failed to meet its recruit-
ment goals because of the high incidence of non-steroidal 
anti-inﬂ  ammatory drug use among potential participants, 
which was exclusionary [7]. A recent trial of latrepirdine 
(formerly dimebon) excluded patients taking medications 
currently approved by the US Food and Drug Adminis-
tration (FDA) for the treatment of AD. Th  is study was 
conducted in part in the US, where there is a high 
prevalence of use of these prescription medications 
among those diagnosed with AD. Th  e data related to 
recruitment for this trial are not yet available.
To increase the appeal to participants seeking new 
treatments, some studies incorporate alternate allocation, 
whereby randomly assigned participants have a greater 
chance of being assigned to an active treatment group 
than the placebo group. Although this may increase the 
appeal of participation to some patients, alternate alloca-
tion also requires increased sample size to maintain 
statistical power and it remains unclear whether this 
strategy abbreviates the total study recruitment period [8].
Design changes made after study initiation
Changes to study conduct after trial initiation but before 
the close of enrollment can impact recruitment. Th  e 
original entry criteria for a phase III trial of tarenﬂ  urbil 
included mild-to-moderate AD patients with an MMSE 
score of between 15 and 26. Th  ree months after 
enrollment began, the MMSE criteria for entry were 
changed to 20 to 26 as a result of ﬁ  ndings from a phase II 
study [9]. Overall trial recruitment occurred from Feb-
ruary 2005 until April 2008. Such changes mid-enroll-
ment can counteract previous recruitment strategies. 
Similarly, stopping a study medication dose prior to 
closing enrollment is likely to impact recruitment. 
Dosing changes, especially those brought about by safety 
concerns, must be communicated to new participants as 
part of informed consent and may deter enrollment of 
new subjects. Th   e high dose of the anti-amyloid antibody 
bapineuzumab was halted for safety reasons prior to 
closure of enrollment in a recent phase III study. 
Alternatively, the publication of positive data related to a 
study drug might improve enrollment. Th  e same phase 
III study of bapineuzumab was still enrolling when data 
were published from phase II eﬃ   cacy [10] and biomarker 
[11] trials. Data on the recruitment rates for the 
bapineuzumab phase III study are not yet available. Trials 
of drugs for which previous positive trials have been 
conducted are likely to enroll quickly. Th   e initial trial of 
memantine in moderate-to-severe AD (MMSE 3 to 14) 
enrolled 252 subjects at 32 US sites over the course of 
9 months [12] and demonstrated a signiﬁ  cant diﬀ  erence 
from placebo on the primary eﬃ   cacy outcomes. Conse-
quently, a trial of memantine in moderate-to-severe AD 
(MMSE 5 to 14) patients taking donepezil eﬃ   ciently 
enrolled 404 patients at 37 trial sites over the course of 
6  months [13].
Barriers to recruitment impact Alzheimer’s disease 
patients and their study partners and shape trial 
populations
Successful trial enrollment faces many barriers, and most 
AD trials struggle to enroll. Th  e ADCS trial of docosa-
hexaenoic acid (DHA) enrolled 400 mild-to-moderate 
AD patients in 8 months, 10 months ahead of schedule, 
making it unique among AD trials. Th  e agent tested in 
this trial funded by the National Institutes of Health was 
considered safe, allowing less restrictive inclusion and 
exclusion criteria. Th  e trial also employed a 60/40 
alternate allocation ratio toward active treatment. Th  e 
factor that may have had the greatest impact on trial 
recruitment, however, was that it was conducted during a 
period in which few other trials in mild-to-moderate AD 
were recruiting and competition for subjects was 
minimal (Joseph Quinn, Oregon Health and Science Uni-
versity, Portland, OR, USA, personal communication).
As discussed, successful recruitment means more than 
just timely fulﬁ  llment of enrollment goals. Trial partici-
pants should be representative of the greater AD 
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trial was 75.6 years. Fifty-three percent of participants 
were female. Th   ese demographic factors are fairly 
represen  tative of the greater AD-suﬀ  ering  population. 
Partici  pants in the DHA trial averaged 14.1 years of 
education. Th  e over-representation of highly educated 
participants is common among AD trial populations [14] 
and stands in stark contrast to epidemiologic studies, 
which consis  tently demonstrate that less than 12 years of 
education is a signiﬁ  cant risk factor for AD [15,16]. In the 
DHA trial, 90% of participants were Caucasian. Faison and 
colleagues [17] examined the race of AD trial participants, 
comparing 737 ADCS trial participants with 10,800 
industry-sponsored trial participants. Th   e authors found 
that only 10% of ADCS and 3% of industry-sponsored 
trial participants were non-Caucasian [17]. Given that 
African-Americans and Hispanics are at greater risk for 
AD than Caucasians [18,19] and that the proportion of 
AD suﬀ  erers who are of minority race or ethnicity will 
increase faster than that of Caucasians in coming decades 
[20], the low rates of minority enrollment in trials must 
be improved.
Among study partners in the DHA trial, 65% were 
female and 68% were spouses of the participant. Th  e 
patient’s primary caregiver most often ﬁ  lls the role of 
study partner and there are roughly 11 million persons in 
the US caring for a dementia patient. Th   e majority of AD 
caregivers are women. Only a fraction of caregivers in the 
US, however, are spouses. Th   e majority of caregivers are 
non-spousal family members, including primarily those 
who care for a parent or a parent-in-law [20]. Th  e high 
representation of spousal caregivers in AD trials is 
striking and important. Trials oﬀ  er patients and families 
an opportunity to feel active and involved in their medical 
care and in medical science’s attempts to help them, others 
like them, and future generations. Many enroll in AD 
trials, however, in pursuit of therapeutic beneﬁ  t. Spousal 
caregivers may have greater motivation than do adult 
children caregivers to pursue new therapeutic options. 
Alternatively, there may be increased barriers to 
participation for adult children caregivers, who are more 
likely to be working full-time, more likely to have young 
families, and thus less likely to have the scheduling 
ﬂ  exibility to participate in clinical trials in the 9-to-5 clinic 
schedules in which they are generally conducted.
Th   e overall diﬀ  erences between the enrolled population 
and the general AD population are troubling. Th  ey 
suggest that the barriers to recruitment and retention 
signiﬁ  cantly shape the population under study and call 
into question the notion that the results of AD trials will 
be broadly applicable beyond a given study. We will next 
examine the various barriers to recruitment of AD trial 
participants, including the patient and the caregiver 
study partner.
Barriers related to the Alzheimer’s disease 
patient-caregiver dyad
Th  e decision to enroll in an AD trial is made by two 
people: the patient and their study partner. In this way, 
recruitment to AD trials is twice as diﬃ   cult as recruit-
ment to clinical trials that enroll only the patient. Th  ose 
who choose to participate in a clinical trial commit 
signiﬁ  cant time and energy. Th   is commit  ment is justiﬁ  ed 
out of hope for personal and societal beneﬁ  t and trust in 
the investigator and study site [21]. Th   e commitment is 
made with an understanding of given risks and 
requirements. Both the patient participant and the study 
partner participant must give informed consent and both 
must commit to full participation. Of course, patient-
caregiver dyads cannot choose to participate unless they 
are aware of studies. At diagnosis, referral to trials is 
uncommon [22]. Th  us, participation by those seeing 
physicians who do not personally conduct trials often 
requires active pursuit of information about study 
opportunities. Yet even when the patient and the study 
partner are aware of trials, they are still likely to 
encounter several barriers to trial participation. Th  e 
barriers and facilitators of AD trial enrollment related to 
patients and caregivers are summarized in Table 2.
Barriers related to the Alzheimer’s disease patient
Many AD patients who wish to participate in a clinical 
trial may not be eligible to do so. AD patients are, by 
deﬁ  nition, older. Older patients are likely to suﬀ  er from 
comorbidities that exclude participation. For example, 
current trials of immunotherapies exclude participants 
for a previous infarct (observed via magnetic resonance 
imaging [MRI]), even if it results in no neurologic sign or 
symptom. Given the high incidence of overlap between 
AD and vascular pathology [23], a substantial number of 
patients who might otherwise qualify for a trial may fail 
to be included, because of this criterion.
Older patients, especially in the US, also take a high 
number of prescription medications, which may similarly 
exclude participation. Even if these patients do not take 
an exclusionary medication at screening, trial protocols 
instruct investigators to enroll only patients whose 
medication proﬁ  les are stable and not likely to change 
through the course of the study. Protocols generally 
include patients taking AD medications, although these 
medications are subject to the same requirements. Th  us, 
when enrolling mild patients who take only an 
acetylcholinesterase inhibitor (AChEI), the investigator is 
forced to consider whether to enroll the patient or start 
memantine (approved only in moderate-to-severe disease) 
to ensure stability through the course of the trial. 
Choosing the latter forces a delay in trial initiation and 
increases the likelihood that the patient will not be 
enrolled due to study closure or another reason.
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enrollment. Late-stage trials generally exclude partici-
pants of earlier-phase studies of the same drug. Similarly, 
most trials of active or passive immunization now 
exclude patients who have previously participated in a 
trial of any AD immunotherapy. In fact, for some ongoing 
trials, choosing to enroll means lifelong participation in 
one and only one trial. For example, the ADCS trial of 
nerve growth factor gene transfer aims to follow 
participants to autopsy and, given that subjects receive a 
therapy that is anticipated to deliver its therapeutic eﬀ  ect 
for as long as the neurons receiving it survive, being 
accepted into other trials is unlikely for recipients of the 
active therapy.
Some patients may be unwilling or unable to participate 
because of the procedures involved in a study. Individuals 
with pacemakers cannot undergo study-required MRIs 
and thus are excluded from trials that require imaging to 
ensure safety or use volumetric measures as mandatory 
outcomes. Many patients experience anxiety related to 
study procedures such as lumbar punctures. One phase II 
investigation of a gamma secretase inhibitor in pro  dromal 
AD is enrolling participants in the randomly assigned 
treatment trial only if they meet speciﬁ  c criteria related to 
cerebrospinal ﬂ  uid protein analysis. Individuals unable or 
unwilling to undergo lumbar puncture are ineligible. 
Neuropsychological testing remains the hallmark of AD 
trials, co-primary outcome measures for all registration 
trials include one cognitive measure, and essentially all 
trials include a broad array of psychometric tests. For 
many trials, cognitive testing batteries are limited to the 
English language. Often, individuals not able to complete 
cognitive testing in the available languages at a study site 
are excluded. Such testing may require 3 to 5 hours to 
complete and can result in frus  tra  tion and distress for the 
participant [24]. In subjects aware of their impairment, 
the reminder of their cognitive struggles can be over  whel-
ming and may result in an unwillingness to participate.
Not all AD patients are aware of their impairment and 
those who lack insight may also lack the capacity to give 
informed consent. Some recent trials of aggressive 
therapies exclude individuals not able to demonstrate the 
capacity to provide consent. In these trials, the inability 
to comprehend trial-related proce  dures and risks is a 
barrier to participation. Th  e majority of AD trials, 
however, facilitate participation by permit  ting a legally 
authorized representative to give the informed consent 
on behalf of a patient who lacks the capacity to do so for 
him- or herself. Most AD patients wish to be involved in 
the decision of whether to participate [25], and dyads 
that enroll in trials are likely to reach a joint decision. 
Although it is not clear how often it occurs, disagreement 
between patients and care  givers about participation can 
be a barrier to enrollment [21].
Table 2. Facilitators and barriers to participation in Alzheimer’s disease clinical trials 
   Participant
Factor Impact  aff  ected  Description
Low trial awareness  −  B  Those not aware of trials cannot participate.
Comorbidities  −  P  Patients with cardiovascular disease, cerebrovascular lesions, or other medical problems 
      are likely to be excluded.
Medications  −  P  Patients taking a high number of prescription medications are likely to be excluded from 
      participation. Specifi  c trials may have other criteria (for example, excluding medications 
      approved for AD) that prevent some patients from participating.
Risks of side eff  ects  −  B  Risks associated with investigational therapies are barriers to patients and their study 
      partners, who often identify risks to the patient as ‘personal’ risk.
Barriers associated with procedures  −  P  Patients may be unwilling to undergo procedures such as lumbar puncture, unable to 
      undergo MRIs, or suff  er associated frustration with cognitive testing.
Risk of placebo  −  B  Some dyads enroll primarily out of hope for access to new treatments. For these persons, 
      the possibility of receiving placebo is a barrier to participation.
Travel and other logistics  −  B  The requirement of attending study visits at the medical center can deter participation.
Language barriers  −   B  Only patients and study partners who both are capable of fl  uent communication in the 
      language acceptable for participation are generally eligible to enroll.
Informed consent  −  P  Patients who are not aware of their impairment may lack the capacity to give informed 
     consent.
Informed consent  +  B  Most trials allow a legally authorized representative to provide informed consent on 
      behalf of the patient.
Access to new treatments  +  B  Many participants enroll in trials in the hope of direct medical benefi  t for the patient. 
Altruism  +  B  The desire to assist medical research is a commonly cited reason for participating in AD 
     trials.
Impact: Facilitator (+), barrier (−). Participant impacted: patient (P) or both (B) patient and caregiver. AD, Alzheimer’s disease; MRI, magnetic resonance imaging.
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Patients who do not have a suitable study partner cannot 
be enrolled in AD trials. Th  e study partner must be an 
individual familiar with the patient’s medical and 
personal situation and the primary caregiver most often 
ﬁ   lls this critical role. At screening, the study partner 
provides an accurate medical history. Following enroll-
ment, they provide transportation to study visits and 
serve as informants in a variety of study procedures and 
outcome measures. Between study visits, they monitor 
study and medication adherence.
Th   e role of the caregiver in the decision to participate 
in an AD trial is as important as that of the patient. 
Often, caregivers choose to participate in AD clinical 
trials out of hope for medical beneﬁ  t for the patient [21, 
26-28]. Other motivations include despera  tion resulting 
from a lack of other treatment options [21,26] and a 
desire to help medical science pursue a cure [21,26,  27, 
29,30]. Trials oﬀ  er the opportunity to interact with AD 
experts and access to new technologies that might not be 
covered by insurance.
If a study partner faces insurmountable barriers to 
participation, then it is unlikely that the patient will 
participate. Caregivers who decline participation cite a 
variety of factors that lead to their decision. Some 
caregivers cite the need to travel to the study site [21], 
and oﬀ  ering car services to facilitate transportation or 
performing at least a portion of study visits in the home 
increases the likelihood that caregivers will support a 
decision to participate [31]. Individuals who report travel 
as a barrier, however, are not necessarily those who reside 
furthest from study sites. Th   is suggests that, at least for 
some caregivers who decline participation, emotional 
and attitudinal factors about the logistics of travel play a 
large role.
Caregivers also face emotional burdens [32-34]. Th  ey 
often cite the fear of side eﬀ  ects for the patient as a 
barrier to participation [21,28]. Many caregivers do not 
distinguish risks or beneﬁ  ts for the patient from risks or 
beneﬁ  ts for themselves [21]. Th   e patient is most often a 
spouse or parent, and the caregiver does not wish to 
increase the patient’s medical burden. Furthermore, 
increased medical burden for the patient is increased 
burden on the primary caregiver.
Finally, some caregivers cite the risk that the patient 
will not beneﬁ  t from participation as a barrier to enroll-
ment [27]. Some caregivers who decline enroll  ment cite 
doubts about the potential eﬃ   cacy of the agent under 
investigation as reason for refusing participation [28]. 
Th  ese caregivers may defer partici  pation in one trial to 
participate in another, more promising study. Th  e same 
individuals are likely to cite the ‘risk’ of placebo as a 
deterrent to participation.
What factors impact trial retention?
Regulatory and ethical guidelines mandate that partici-
pants can withdraw their consent to participate in a 
clinical study at any time. Th   erefore, good retention begins 
prior to enrollment, by recruiting study partici  pants who 
are likely to complete a trial. Once trial conduct is initiated, 
making participation as convenient as possible for subjects 
and study partners optimizes retention.
Steps should be taken to inform participants of their 
value and the value of the research in which they are 
participating. Newsletters informing participants of trial 
progress can facilitate the feeling of being part of a larger 
agenda. For centers or investigators conducting multiple 
trials, annual luncheons honoring research participants 
can be eﬀ  ective retention tools, although these events 
must be conducted with sensitivity to participant conﬁ  -
den  tiality and privacy.
A variety of factors can impact trial retention. Examples 
of trials that had poor retention exist, but often these 
trials faced extenuating challenges. A trial in mild-to-
moderate AD of atorvastatin enrolled 98 participants, of 
whom 15 withdrew consent prior to random assignment 
‘primarily to participate in other trials’ [35]. Similarly, the 
ADCS trial of dihydroepiandrosterone initially recruited 
58 participants, but only 33 completed the 12-month trial 
[36]. Fifty-three percent of subjects randomly assigned to 
placebo dropped out of the study prior to completion, 
and the authors hypothesized that the high rate of 
dropout may have been the result of the widespread 
availability of FDA-approved AChEI therapies during 
study conduct [36].
We examined the retention rates in a sample of AD 
trials (Table 3). Although some trials may include a low 
dose without expectation of therapeutic beneﬁ  t, we chose 
to combine all active treatment doses in a single category. 
In the very few occasions in which two active treatments 
were tested against placebo [37,38], we combined all 
active treatments in a single group. In cases in which 
participants completed a study oﬀ  -medication, they have 
been included as completers whenever possible. Impor-
tantly, this summary is limited largely to trial reports in 
primary manuscripts rather than analysis of raw data and 
should be interpreted accordingly.
Table 3 shows that the majority of subjects who enroll 
in AD trials are retained through trial completion and 
that, across disease severities, these rates do not 
substantively vary. MCI trials had an average retention 
rate of 71.6%, mild-to-moderate AD trials 77.7%, and 
moderate-to-severe and severe AD trials 75.4%. One 
might expect that, independent of disease severity, reten-
tion is easier in shorter trials. Even among some of the 
longest trials conducted, however, retention rates are 
high. Alternatively, some of the lower rates are for 
6-month studies.
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between the treatment and placebo groups in the percen-
tage of participants who completed the trial [13,39]. Th  is 
supports the idea that altruism is a motivating factor for 
enrolling and continuing participation. If a patient or 
caregiver was interested in participation solely for the 
sake of gaining access to a new therapy, they might be 
likely to drop out of a trial if they concluded that they 
were randomly assigned to the placebo group (whether 
they were correct or not) or if they perceived that the 
patient is declining despite receiving study medication.
Recent analyses of the ADCS MCI trial of donepezil 
and vitamin E by Edland and colleagues [40] suggest that 
a variety of factors within a trial may indicate patients 
who will drop out prior to study completion. Th  e  authors 
found that the characteristics of participants who were 
likely to drop out were non-Caucasian race, less than 
high school education, and being unmarried (that is, 
having an adult child or child-in-law as a study partner). 
Furthermore, the analysis suggested that participants 
recruited to commercial trial sites (as opposed to 
academic sites) were at increased risk to drop out of a 
trial. Dropout rates at commercial sites were nearly 
double those of sites that were AD research centers 
funded by the National Institute on Aging [40]. In line 
with their analyses, in the trials that we reviewed, those 
with the largest study size (and as such were most likely 
to enlist non-academic sites) had the lowest retention 
Table 3. Retention rates from a sample of Phase II and Phase III Alzheimer’s disease clinical trials
         Trial
   Study  Active  Placebo  length, 
  Treatment under study  enrollment  completers  completers  months
Mild cognitive impairment  Rofecoxib [54]  1,457  687/725 = 0.95  702/732 = 0.96  48
  TRIMCI study of trifusal [7]  257  104/129 = 0.81  119/128 = 0.93  18
  Donepezil [57]  270  90/133 = 0.68  114/137 = 0.83  6
  Vitamin E and donepezil [38]  790  346/510 = 0.68  193/259 = 0.74  36
  Rivastigmine [55]  1,018  312/508 = 0.61  346/510 = 0.68  48
  Donepezil [58]  821  226/409 = 0.55  273/412 = 0.66  12
  Two studies of galantamine [56]  2,057  476/1,029 = 0.46  543/1,028 = 0.53  24
Mild-to-moderate AD  Dimebon [59]  183  78/89 = 0.88  77/94 = 0.82  4
  Gamma secretase inhibitor [62]  51  32/36 = 0.89  12/15 = 0.80  4
  Rosiglitazone [65]  518  106/122 = 0.87  336/389 = 0.86  6
  High-dose B vitamin [66]  409  204/240 = 0.85  140/169 = 0.83  18
  Rivastigmine patch [63,64]  1,195  704/893 = 0.79  266/302 = 0.88  6
  Estrogen replacement [6]  120  65/81 = 0.80  32/39 = 0.82  15
  Galantamine [69]  978  539/692 = 0.78  240/286 = 0.84  5
  Rofecoxib [37]  351  179/240 = 0.74  88/111 = 0.79  12
  DHA (Joseph Quinn, personal communication)  402  178/241 = 0.74  129/161 = 0.80  18
  Bapineuzumab [10]  234  92/122 = 0.75  87/107 = 0.81  18
  AN1792 [61]  372  223/299 = 0.74  53/73 = 0.73  12
  Idebenone [60]  536  281/407 = 0.69  96/129 = 0.74  12
  Atorvastatin [39]  640  207/314 = 0.66  245/326 = 0.75  18
  Galantamine [70]  636  266/423 = 0.63  172/213 = 0.81  6
  Tarenfl  urbil [9]  1,684  506/862 = 0.59  540/822 = 0.66  18
Moderate-to-severe/Severe AD  Selegeline/Alpha tocopherol [71] CDR 2  341  240/257 = 0.93  78/84 = 0.93  24
  Donepezil [72] MMSE 5 to 17  291  121/144 = 0.84  126/146 = 0.86  6
  Donepezil [5] MMSE 1 to 10  249  95/128 = 0.74  99/120 = 0.82  6
  Memantine [67] MMSE 5 to 14  350  134/178 = 0.75  126/172 = 0.73  6
  Memantine [12] MMSE 3 to 14  252  97/126 = 0.77  84/126 = 0.67  7
  Donepezil [68] MMSE 1 to 12  343  117/176 = 0.66  127/167 = 0.76  6
  Memantine [13] MMSE 5 to 14  404  172/203 = 0.85  150/201 = 0.75  6
AD, Alzheimer’s disease; CDR, Clinical Dementia Rating; DHA, docosahexaenoic acid; MMSE, Mini-Mental State Examination.
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mean retention rate of 70.6%. Alternatively, the smallest 
trials examined (fewer than 300) had higher rates of 
retention (81.4%). Similarly, trials conducted by the 
ADCS had an 81.2% mean retention rate. Th  e  remaining 
trials averaged a 73.2% retention.
Outlook for the future
What is the available pool of patients for Alzheimer’s 
disease trials?
Many promising therapies are in clinical development for 
AD and more will enter clinical trials in coming years. To 
plan the recruitment of adequate subject populations for 
these trials, it will be necessary to better understand the 
pool of eligible patients qualiﬁ   ed to participate. More 
than 400,000 Americans are diagnosed with AD annually 
[41]. Hence, investigators might assume that they have an 
ample (and growing) supply of participants for trials. 
Among all dementia patients, however, roughly half are 
moderately severe or more advanced in their disease 
[42,43] and therefore fail to meet the mild-to-moderate 
category for which most trials currently recruit. Th  e 
majority of all AD patients are older than 75 years [43], 
increasing the likelihood of exclusion for reasons such as 
comorbidities or prohibited medications. In fact, analyses 
of general clinical AD populations suggest that only 10% 
to 13% are eligible for clinical trials [44,45]. In sum, the 
pool of eligible trial participants for AD trials is limited.
In 2009, at least seven phase III trials (of ﬁ  ve drugs) 
recruiting in the US required a combined total of 8,510 
participants (solanezumab [LY2062430] n  =  1,000 
[ClinicalTrials.gov ID NCT00905372] and n  =  1,000 
[NCT00904683]; semagecestat [LY450139] n  =  1,100 
[NCT00762411] and n = 1,700 [NCT01035138]; bapineu-
zumab n  =  1,300 [NCT00574132] and n  =  1,000 
[NCT00575055]; dimebon n  =  1,050 [NCT00829374]; 
and intravenous immunoglobulin n  =  360 
[NCT00818662] [1]). Th  ere were more, though smaller, 
phase II studies. Screening ratios are generally better 
than 2:1 (2 patients screened to enroll 1) (Table 1), but 
the fact remains that a signiﬁ  cant number of patients 
recruited will not be enrolled. Th   us, if one considers the 
newly diagnosed patients each year, the barriers to 
enrollment, and the number of participants needed as 
multiple trials are conducted simultaneously, it is clear 
that the recruitment needs for AD clinical trials will 
remain a challenge that results in competition for eligible 
subjects. Strategies to overcome the current barriers to 
recruitment must be developed.
How can trial recruitment be optimized?
Th   e most straightforward approach to improving the rate 
of enrollment is to increase the number of trial sites. AD 
trials have become increasingly ‘global’, enrolling from 
multiple countries and continents within single studies. 
Th   is change brings potential methodological [46] as well 
as ethical challenges when less industrialized nations are 
involved for which access to the drug (once it is approved) 
is not likely [47] (Declaration of Helsinki). Moreover, trial 
recruitment is diﬃ   cult in all countries, not just the US 
[48]. It has been shown that, with increasing trial site 
number, the likelihood of placebo decline is reduced [49]. 
Furthermore, expanding the number of trial sites results 
in the inclusion of sites that are not focused on AD as a 
therapeutic area.
AD trials are optimally performed at trial sites experi-
enced in their speciﬁ  c conduct by staﬀ  s well versed in the 
issues AD patients and their families face. Trials can be 
designed to facilitate participation for the subject and 
their study partner. Performing visits in the home and 
otherwise limiting travel hassles will increase the willing-
ness to participate among caregivers.
Awareness of trials must be increased. Eﬀ  orts  to 
increase awareness should target both patients and care-
givers. Th  e fact that most caregivers are adult children 
but most study partners are spouses indicates that there 
remains a large number of uninformed or unwilling 
potential participant dyads. Social media may provide an 
avenue to speciﬁ   cally target adult children caregivers. 
Th  e Wisconsin Registry for Alzheimer’s Prevention has 
successfully enrolled more than 1,400 middle-aged adult 
children of AD patients in a natural history study [50], 
and the use of television advertising has been an eﬀ  ective 
means of recruitment. Similarly, web-based patient 
registries such as www.patientslikeme.com [51] have 
been used eﬀ  ectively in other therapeutic areas. Internet 
use among those over the age of 65 is increasing, and 
‘wired seniors’ are likely to seek health-care information 
speciﬁ   cally when online [52]. AD models of registries 
have been proposed and could target MCI and mild-stage 
AD potential participants and caregivers and also 
potential participants in prevention trials, such as baby 
boomers [53].
Th  e advantage of disseminating the message of the 
value of clinical trials is to diversify the reasons why 
people enroll. Th   e more reasons a person has for being in 
a trial, the more likely he or she is to enroll and, over 
time, stay in a trial. As participants experience adverse 
events and the eﬀ  orts of study visits, those participants 
whose reasons for enrollment include trust in the 
investigator and a desire to help others are more likely to 
stay in a trial than are patients whose sole motivation is 
beneﬁ   t to their health. Th  is is especially true in AD 
clinical trials in which, to date, therapeutic beneﬁ  t has 
been elusive.
Eﬀ  ective methods to limit competition among trials, 
facilitate enrollment, and match eligible candidates with 
appropriate trials would improve recruitment and 
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Agencies to ﬁ  ll such needs could have a major impact on 
clinical research. Such agencies, however, should be 
supported by federal and state governments, not for-
proﬁ  t entities, and would thus be free of private corporate 
interests.
Conclusions
In summary, clinical trials in AD face a variety of 
challenges to recruitment and retention. Many trials 
struggle to complete enrollment in a timely fashion 
despite substantial eﬀ   ort. Trial enrollment may not 
repre  sent the greater disease-suﬀ  ering population, and 
this may result in trial ﬁ   ndings that are not readily 
applicable beyond the study. AD trial retention is largely 
eﬀ  ective, although some variation does exist and is likely 
related to the population recruited and the caliber of 
study conduct. Responses to these challenges and 
improvement to recruitment and retention can and 
should be made. All eligible subjects must be made aware 
of participation opportunities, and trials must be 
designed in a manner that makes participation feasible 
for patient-caregiver dyads.
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